Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125550061 | 12555006 | 1 | I | 20160629 | 20160714 | 20160714 | EXP | IT-NOVPHSZ-PHHY2016IT085138 | IT-OCTA-LIT09916IT | OCTAPHARMA | MARCHETTI JC, CONTI A, BORSARI S, REGGIANI C, COPPINI M, PELLACANI G. RITUXIMAB IN RECALCITRANT PEMPHIGUS: A CASE SERIES EXPERIENCE. CLINICAL DERMATOLOGY 2016; 4 (1): 32-37. | 55.00 | YR | A | M | Y | 0.00000 | 0 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125550061 | 12555006 | 1 | PS | HUMAN NORMAL IMMUNOGLOBULIN (IV) | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 0 | SOLUTION FOR INFUSION | ||||||||||
| 125550061 | 12555006 | 2 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | 0 | ||||||||||||
| 125550061 | 12555006 | 3 | SS | PREDNISONE. | PREDNISONE | 1 | 0 | ||||||||||||
| 125550061 | 12555006 | 4 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | 0 | ||||||||||||
| 125550061 | 12555006 | 5 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | 0 | ||||||||||||
| 125550061 | 12555006 | 6 | SS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 375 MG/M2 | 0 | ||||||||||
| 125550061 | 12555006 | 7 | C | HYDROCORTISONE SODIUM SUCCINATE | HYDROCORTISONE SODIUM SUCCINATE | 1 | Intravenous (not otherwise specified) | 0 | 200 | MG | |||||||||
| 125550061 | 12555006 | 8 | C | CHLORPHENAMINE MALEATE | CHLORPHENIRAMINE MALEATE | 1 | Intravenous (not otherwise specified) | 0 | 10 | MG | 1X | ||||||||
| 125550061 | 12555006 | 9 | C | CALCIUM GLUCONATE. | CALCIUM GLUCONATE | 1 | Intravenous (not otherwise specified) | 0 | 94 | MG | 1X |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125550061 | 12555006 | 1 | Pemphigus |
| 125550061 | 12555006 | 2 | Pemphigus |
| 125550061 | 12555006 | 3 | Pemphigus |
| 125550061 | 12555006 | 4 | Pemphigus |
| 125550061 | 12555006 | 5 | Pemphigus |
| 125550061 | 12555006 | 6 | Pemphigus |
| 125550061 | 12555006 | 7 | Premedication |
| 125550061 | 12555006 | 8 | Premedication |
| 125550061 | 12555006 | 9 | Premedication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125550061 | 12555006 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125550061 | 12555006 | Cytomegalovirus infection | |
| 125550061 | 12555006 | Staphylococcal sepsis | |
| 125550061 | 12555006 | Suspected transmission of an infectious agent via product |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |